Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Search
Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
The Unwearable Collection - The GPP patient experience
The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.
Bernard Mental Health Impact
Harold and Friends learn about how living with multiple health conditions can impact mental health
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
Edda Dankmeyer
Edda Dankmeyer is our Lead of Sustainable Development Communications. She tells us where her passion for sustainability comes from, why she joined us, and how sustainable development can be a key differentiator for the company.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
History video
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Meet the BD&L Team 2019
Hear from our team and find out more about our approach to partnering.
Lamb-shanks video
This succulent, heart dish is packed full of flavour and sure to be a hit with the whole family.
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions